Gemcitabine

• Description:

  Gemcitabine (LY 188011) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine inhibits DNA synthesis and repair, resulting in autophagyand apoptosis[1][2].

• Product Name Alternative:

  LY 188011

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Apoptosis; Autophagy; DNA/RNA Synthesis; Nucleoside Antimetabolite/Analog

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Autophagy; Cell Cycle/DNA Damage

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Gemcitabine.html

• Purity:

  99.94

• Solubility:

  DMSO : 200 mg/mL (ultrasonic) |Ethanol : 12.5 mg/mL (ultrasonic) |H2O : 6.25 mg/mL (ultrasonic; warming)

• Smiles:

  NC (C=CN1[C@H]2C (F) (F) [C@H] (O) [C@@H] (CO) O2) =NC1=O

• Molecular Formula:

  C9H11F2N3O4

• Molecular Weight:

  263.20

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Wang H, et al. Enhanced efficacy of Gemcitabine by indole-3-carbinol in pancreatic cell lines: the role of human equilibrativenucleoside transporter 1. Anticancer Res. 2011 Oct;31 (10) :3171-80.|[2]Yip-Schneider MT, et al. Dimethylaminoparthenolide and Gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer. BMC Cancer. 2013 Apr 17;13:194.|[3]Gagnadoux F, et al. Safety of pulmonary administration of gemcitabine in rats. J Aerosol Med. 2005 Summer;18 (2) :198-206|[4]Yusheng Cai, et al. Elimination of senescent cells by β-galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice. Cell Res. 2020 Jul;30 (7) :574-589.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Citation 01:

  ACS Biomater Sci Eng. 2025 Feb 10;11 (2) :1222-1231.|ACS Infect Dis. 2025 Oct 30.|Acta Biochim Biophys Sin (Shanghai) . 2021 Mar 2;53 (3) :317-324.|Acta Biomater. 2025 Aug 27:S1742-7061 (25) 00640-3.|Acta Pharmacol Sin. 2024 Apr;45 (4) :844-856.|Adv Mater. 2021 May;33 (18) :e2100949.|Adv Mater. 2025 Jul 4:e2505231.|Adv Sci (Weinh) . 2023 Apr;10 (12) :e2206004.|Adv Sci (Weinh) . 2023 Nov;10 (33) :e2302498.|Adv Sci (Weinh) . 2023 Oct;10 (30) :e2303872.|Adv Sci (Weinh) . 2024 Aug 23:e2400156.|Adv Sci (Weinh) . 2024 Nov 28:e2407519.|Adv Sci (Weinh) . 2025 Jan 21:e2409173.|Adv Sci (Weinh) . 2025 May 20:e01042.|Adv Ther. 2024 Jul 18.|Aging. 2020 Aug 28;12 (16) :16304-16325.|Am J Cancer Res. 2020 Nov 1;10 (11) :3896-3910.|Am J Cancer Res. 2020 Apr 1;10 (4) :1182-1193.|Anticancer Drugs. 2025 Jun 13.|Arch Toxicol. 2023 Dec;97 (12) :3209-3226.|ÁREA DE FARMACIA Y TECNOLOGÍA FARMACÉUTICA. DEPARTAMENTO DE INGENIERÍA. 2020 Oct.|Biochem Pharmacol. 2021 Jul:189:114085.|Biochem Pharmacol. 2021 Nov:193:114813.|Biochem Pharmacol. 2024 Jun:224:116234.|Biochem Pharmacol. 2025 Jul 18:241:117182.|Biochem Pharmacol. 2025 Jul 18:241:117183.|Biochim Biophys Acta Mol Basis Dis. 2025 Apr 30:167881.|Biochim Biophys Acta Mol Basis Dis. 2025 Mar 31;1871 (5) :167814.|Bioengineering (Basel) . 2025 Oct 19;12 (10) :1121.|Biol Pharm Bull. 2022 Mar 1;45 (3) :309-315.|Biomaterials. 2022 Oct:289:121800.|Biomed Pharmacother. 2019 Sep:117:109185.|Biomed Pharmacother. 2022 Apr:148:112713.|Biomed Pharmacother. 2023 Oct:166:115389.|Bioorg Chem. 2025 May 29:163:108636.|Bioorg Chem. 2025 Sep 17:165:109010.|bioRxiv. 2023 Feb 28.|bioRxiv. 2023 Feb 7.|bioRxiv. 2023 Sep 5.|bioRxiv. 2024 Aug 6:2024.03.21.586169.|bioRxiv. 2024 June 12.|bioRxiv. 2025 April 17.|bioRxiv. 2025 February 22.|bioRxiv. 2025 Jan 27:2025.01.26.634889.|bioRxiv. 2025 January 02.|bioRxiv. 2025 Mar 13:2025.03.11.642569.|bioRxiv. 2025 Oct 9.|bioRxiv. 2025 Sep 21.|bioRxiv. 2025 Sep 24.|BJU Int. 2025 Nov 3.|Breast Cancer Res Treat. 2023 Jul;200 (2) :193-201.|Cancer Cell Int. 2025 Oct 15;25 (1) :1-14.|Cancer Commun (Lond) . 2025 May 29.|Cancer Lett. 2022 Jun 28;536:215651.|Cancer Lett. 2023 Feb 1:554:216023.|Cancer Lett. 2024 Nov 28:605:217284.|Cancer Lett. 2025 Apr 16:217726.|Cancer Lett. 2025 May 28:618:217633.|Cancer Med. 2019 Oct;8 (13) :5903-5915.|Cell Biomater. 2025 Jul 22.|Cell Commun Signal. 2025 Nov 27;23 (1) :513.|Cell Death Dis. 2025 Jan 18;16 (1) :28.|Cell Death Dis. 2025 Jul 15;16 (1) :526.|Cell Death Dis. 2025 Jul 4;16 (1) :492.|Cell Death Discov. 2021 May 1;7 (1) :89.|Cell Mol Life Sci. 2021 Dec;78 (23) :7505-7518.|Cell Mol Life Sci. 2024 Oct 5;81 (1) :417.|Cell Oncol (Dordr) . 2025 Jun;48 (3) :655-671.|Cell Prolif. 2021 May;54 (5) :e13038.|Cell Rep Med. 2023 Feb 21;4 (2) :100911.|Cell Rep Med. 2023 Oct 17;4 (10) :101234.|Cell Rep Med. 2025 Apr 2:102053.|Cell Rep Med. 2025 Sep 19:102357.|Cell Rep. 2022 Aug 16;40 (7) :111194.|Cell Rep. 2024 Apr 23;43 (4) :114088.|Cell Rep. 2025 Jun 27;44 (7) :115925.|Cell Rep. 2025 Nov 25;44 (11) :116476.|Cell Res. 2020 Jul;30 (7) :574-589.|Cell Signal. 2025 Jun 26:111965.|Chem Biol Interact. 2018 Jun 25:290:44-51.|Chem Eng J. 2023 Nov 17, 147466.|Chem Eng J. 2024 Sep 1.|Chin Chem Lett. 2017 March.|Chinese Pharmacological Bulletin. 2017, 33 (6) : 788-792.|Clin Epigenetics. 2025 May 6;17 (1) :77.|Clin Transl Oncol. 2022 Nov;24 (11) :2231-2240.|Commun Biol. 2024 Dec 3;7 (1) :1612.|Curr Issues Mol Biol. 2024 Dec 11;46 (12) :13951-13969.|Discov Oncol. 2025 Jan 3;16 (1) :3. |DNA Cell Biol. 2022 Feb;41 (2) :116-127.|Elife. 2022 May 3;11:e69255.|Eur J Med Res. 2025 Aug 4;30 (1) :704.|Eur J Pharm Sci. 2025 Jan 1:204:106969. |Eur J Pharmacol. 2025 Dec 5:1008:178303.|Eur Rev Med Pharmacol Sci. 2019 Jan;23 (2) :649-659. |Exp Cell Res. 2020 Dec 1;397 (1) :112335.|Front Oncol. 2021 Jul 13:11:704042.|Gastroenterology. 2021 Nov;161 (5) :1601-1614.e23.|Heliyon. 2024 Jun 28;10 (13) :e33835.|Hepatology. 2019 May;69 (5) :1995-2012. |Immun Inflamm Dis. 2023 Jun;11 (6) :e872.|Inflamm Res. 2022 Dec;71 (12) :1547-1557.|Int Immunopharmacol. 2023 Oct:123:110709.|Int J Biol Sci. 2022 Jul 4;18 (11) :4301-4315.|Int J Biol Sci. 2022; 18 (1) :43-64.|Int J Clin Exp Pathol. 2017;10 (3) :3033-3042.|Int J Hyperthermia. 2024 Feb 12;41 (1) :2316085.|Int J Med Sci. 2022 Jan 4;19 (2) :286-298.|Int J Nanomedicine. 2025 Jun 4:20:7169-7183.|Int J Oncol. 2026 Jan;68 (1) :10.|Invest New Drugs. 2022 Apr;40 (2) :274-289.|Invest New Drugs. 2025 Jun;43 (3) :728-741.|iScience. 2022 Sep 6;25 (10) :105081.|iScience. 2025 Apr 23;28 (6) :112509.|iScience. 2025 Nov 23.|J Adv Res. 2025 Nov 5:S2090-1232 (25) 00874-4.|J Adv Res. 2025 Oct 16:S2090-1232 (25) 00818-5.|J Biol Chem. 2017 Jun 2;292 (22) :9136-9149.|J Biol Chem. 2023 Aug;299 (8) :104984.|J Biomed Inform. 2023 Jun:142:104383.|J Cancer Res Clin Oncol. 2024 Jul 13;150 (7) :348.|J Cannabis Res. 2024 May 8;6 (1) :22.|J Clin Invest. 2024 Mar 7;134 (10) :e172716.|J Control Release. 2023 Sep:361:161-177.|J Ethnopharmacol. 2024 Jun 28:328:118075.|J Ethnopharmacol. 2026 Feb 28:357:120890.|J Exp Clin Cancer Res. 2021 Nov 25;40 (1) :373.|J Exp Clin Cancer Res. 2022 Oct 5;41 (1) :293.|J Exp Clin Cancer Res. 2023 May 4;42 (1) :111.|J Immunother Cancer. 2024 Sep 4;12 (9) :e009318.|J Mater Chem B. 2023 Nov 8;11 (43) :10355-10361.|J Med Chem. 2024 Sep 12;67 (17) :15816-15836.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|J Nanobiotechnology. 2022 Jul 6;20 (1) :315.|J Pancreatol. 2023 Dec 12.|J Pharm Biomed Anal. 2025 Nov 15:265:117063.|J Pharm Pharmacol. 2025 Jan 23:rgae149.|J Transl Med. 2023 Nov 21;21 (1) :838.|J Transl Med. 2024 Dec 25;22 (1) :1147.|J Transl Med. 2024 Dec 3;22 (1) :1095.|J Transl Med. 2024 Jan 13;22 (1) :55.|MAbs. 2024 Jan-Dec;16 (1) :2438173.|Mater Today Bio. 2025 Jul 28:34:102153.|Mater Today Nano. 2024 Aug.|Microbiol Spectr. 2025 Aug 12.|Mol Cancer. 2023 Dec 4;22 (1) :195.|Mol Cancer. 2024 Apr 29;23 (1) :86.|Mol Cancer. 2024 Jan 10;23 (1) :12.|Mol Cancer. 2024 Sep 30;23 (1) :215.|Mol Carcinog. 2024 Apr;63 (4) :772-784.|Mol Carcinog. 2024 Oct;63 (10) :1953-1966.|Mol Immunol. 2019 May:109:140-148.|Mol Med. 2025 Apr 4;31 (1) :126.|Mol Pharm. 2021 Jul 5;18 (7) :2495-2506.|Mol Ther. 2025 Sep 10:S1525-0016 (25) 00732-4.|Molecules. 2022 Oct 13;27 (20) :6849.|Nanoscale Horiz. 2025 Jun 23;10 (7) :1465-1477.|Nat Commun. 2024 Oct 2;15 (1) :8540.|Nat Commun. 2025 Jul 17;16 (1) :6592.|Nat Med. 2024 Mar;30 (3) :749-761.|Nat Metab. 2025 Nov 13.|Nature. 2019 Oct;574 (7777) :264-267. |Naunyn Schmiedebergs Arch Pharmacol. 2019 May;392 (5) :615-622.|Onco Targets Ther. 2020 Sep 28;13:9543-9558.|Oncogene. 2023 Oct;42 (42) :3113-3126.|Oncol Lett. 2021 Aug;22 (2) :626.|Oncol Rep. 2022 Feb;47 (2) :33.|Oncol Res. 2024 Nov 13;32 (12) :1867-1879.|Oxid Med Cell Longev. 2022 Sep 29;2022:3243647.|Patent. US20210260092A1.|Patent. US20220362387A1.|Patent. US20240344020A1|Patent. US20240344020A1.|PeerJ. 2025 May 30:13:e19517.|Pharmaceutics. 2025 Jul 25;17 (8) :967.|Pharmacol Res. 2024 May 9:204:107208.|Phytomedicine. 2022 Sep:104:154323.|Phytomedicine. 2024 Apr 26:155656.|Phytomedicine. 2024 Jun:128:155527.|Phytomedicine. 2024 Sep 7:135:156022.|Phytomedicine. 2025 Oct 8:148:157389.|Phytother Res. 2022 Aug;36 (8) :3313-3324.|Redox Biol. 2021 Jan;38:101807.|Redox Biol. 2024 May 17:73:103200.|Res Sq. 2024 Sep 05.|Res Sq. 2025 Jul 30.|Res Sq. 2025 Mar 26.|Res Sq. 2025 Oct 29.|Res Sq. 2025 Sep 7.|Research (Wash D C) . 2025 Jul 30:8:0809.|Research Square Preprint. 2021 Aug.|Research Square Preprint. 2021 Nov.|Research Square Preprint. 2024 Aug 19.|Research Square Preprint. 2024 Jan 8.|Research Square Preprint. 2024 Nov 06.|Research Square Print. October 6th, 2022.|RSC Adv. 2022 Oct 3;12 (43) :28104-28112.|RSC Pharm. 2025 Oct 9.|Sci Adv. 2024 Dec 13;10 (50) :eadq4274.|Sci Adv. 2024 Jul 5;10 (27) :eadl1197.|Sci Rep. 2024 Nov 29;14 (1) :29661.|Sci Rep. 2025 Sep 26;15 (1) :33008.|Sci Transl Med. 2021 Jan 20;13 (577) :eaba7401.|SLAS Discov. 2018 Aug;23 (7) :687-696. |SSRN. 2025 Nov 13.|Stem Cells Int. 2023 Jan 30:2023:6510571.|Surgery. 2024 May;175 (5) :1264-1275.|Technol Cancer Res Treat. 2024 Jan-Dec:23:15330338241241935.|Theranostics. 2021 Mar 24;11 (12) :5650-5674.|Transl Lung Cancer Res. 2024 Oct 31;13 (10) :2698-2712.|Transl Lung Cancer Res. 2025 Jun 30;14 (6) :2159-2179.|Transl Oncol. 2020 Sep;13 (9) :100804.|Transl Oncol. 2024 Jan:39:101803.|Transl Res. 2023 May:255:66-76.|Universidad de Granada. 2023 Mar 27.|University of Brescia. 2023 Feb 2.|University of Kansas. 2025.|University of Western Australia. 2024 Jul 28.|View. 2023 Nov 15.|Acta Biomater. 2023 Jul 1:164:407-421.|Acta Pharm Sin B. 2023 Oct;13 (10) :4253-4272.|Adv Sci (Weinh) . 2022 May;9 (15) :e2105894.|Biomed J. 2020 Aug;43 (4) :368-374.|Br J Pharmacol. 2021 Jun;178 (12) :2496-2515.|Cancer Lett. 2024 Apr 10:587:216696.|Cancer Res. 2023 Sep 15;83 (18) :3059-3076.|Cell Death Dis. 2025 Aug 6;16 (1) :592.|Chem Biol Interact. 2024 Jan 5:387:110816.|Eur J Pharmacol. 2025 Sep 15:1003:177942.|FASEB J. 2025 Jul 31;39 (14) :e70802.|Heliyon. 2022 Jun 8;8 (6) :e09643.|Int J Biol Macromol. 2025 Dec;334 (Pt 1) :148793.|Int J Cancer. 2024 Jul 15;155 (2) :324-338.|Int J Nanomedicine. 2023 Jul 20:18:3989-4005.|J Gastroenterol. 2025 May;60 (5) :641-657.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|J Pharmacol Exp Ther. 2018 Oct;367 (1) :20-27.|JCI Insight. 2022 Nov 22;7 (22) :e159419.|Molecules. 2023 Nov 12;28 (22) :7552.|Onco Targets Ther. 2019 Jun 12:12:4585-4593.|Oncol Lett. 2023 Sep 20;26 (5) :473.|Oncotarget. 2017 Oct 6;8 (52) :90185-90196. |PLoS Negl Trop Dis. 2019 Aug 20;13 (8) :e0007681. |SSRN. 2024 Mar 14.|Urol Oncol. 2021 Mar;39 (3) :194.e1-194.e7.

• CAS Number:

  95058-81-4